Advances in the treatment of ST Elevation Myocardial Infarction in the UK.

The treatment of acute coronary occlusion with Primary PCI has been a major factor in improving outcomes of patients suffering STEMI in the last 15 years, and is the standard treatment for patients suffering STEMI in the UK. Treatment is beneficial for patients presenting within 12 hours of the onset of symptoms, with the goal being opening of the occluded artery within 150 min of the call for help. Opening of the occluded artery is typically completed with a drug-eluting stent followed by administration of antiplatelet medications for 12 months. Procedures are performed using the radial artery which is associated with improved outcomes compared to vascular access via the femoral artery. Evidence is growing to support full revascularisation including the treatment of severe narrowing in other blood vessels as well as the culprit vessel.

Impact of COVID-19 on primary percutaneous coronary intervention centres in the UK: a survey.

During the coronavirus disease (COVID-19) pandemic, the British Cardiovascular Society/British Cardiovascular Intervention Society and the British Heart Rhythm Society recommended to postpone non-urgent elective work and that primary percutaneous coronary intervention (PCI) should remain the treatment of choice for patients with ST-segment elevation myocardial infarction (STEMI). We sought to determine the impact of COVID-19 on the primary PCI service within the United Kingdom (UK). A survey of 43 UK primary PCI centres was performed and a significant reduction in the number of cath labs open was found (pre-COVID 3.6±1.8 vs. post-COVID 2.1±0.8; p<0.001) with only 64% of cath labs remained open during the COVID-19 pandemic. Primary PCI remained first-line treatment for STEMI in all centres surveyed.

Radial Versus Femoral Access for Acute Coronary Syndromes.

The feasibility and safety of transradial coronary intervention was demonstrated soon after the description of the transfemoral approach, despite which the use of the femoral artery still dominates in acute coronary syndrome intervention. The advantages of using the radial artery are virtual elimination of access site complications and an important reduction in bleeding, both of which are of utmost importance to the patient with myocardial infarction. Randomised controlled trials have now documented what seems inherent; that transradial intervention should bring with it an advantage in terms of morbidity and mortality in this cohort. The potential disadvantages in terms of speed of procedure and radiation exposure are negated by operator experience. Registries have illustrated that conversion on a large scale from the femoral to the transradial approach is safe and saves lives, most convincingly so in acute coronary syndrome intervention. This review discusses the potential benefits and risks of the alternative access sites in acute patients and explores how these are borne out in the published data.

Pre-procedural fasting for coronary interventions: is it time to change practice?

INTRODUCTION: Traditionally, patients are kept nil-per-os/nil-by-mouth (NPO/NBM) prior to invasive cardiac procedures, yet there exists neither evidence nor clear guidance about the benefits of this practice. OBJECTIVES: To demonstrate that percutaneous cardiac catheterisation does not require prior fasting. METHODS: The data source is a retrospective analysis of data registry of consecutive patients who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) and stable angina at two district general hospitals in the UK with no on-site cardiac surgery services. RESULTS: A total of 1916 PCI procedures were performed over a 3-year period. None of the patients were kept NPO/NBM prior to their coronary procedures. The mean age was 67±16 years. 1349 (70%) were men; 38.5% (738/1916) had chronic stable angina, while the rest had ACS. 21% (398/1916) were diabetics while 53% (1017/1916) were hypertensive. PCI was technically successful in 95% (1821/1916) patients. 88.5% (1697/1916) had transradial approach. 77% (570/738) of elective PCI patients were discharged within 6 h postprocedure. No patients required emergency endotracheal intubation and there were no occurrences of intraprocedural or postprocedural aspiration pneumonia. CONCLUSIONS: Our observational study demonstrates that patients undergoing PCI do not need to be fasted prior to their procedures.

Troubleshooting and problem solving: the nuances of the Epiducer.

BACKGROUND AND AIMS: The study shows placement of spinal cord stimulators using an Epiducer for placement of multiple cylindrical leads or single S-8 paddle leads. It also gives tips for problem-solving Epiducer use. OBJECTIVE: The study aims to suggest techniques that may help in solving commonly occurring difficulties with Epiducer use. DESIGN: This is a retrospective review. SETTING: These procedures were commonly performed in an outpatient surgery center or hospital setting. CONCLUSION: Some problems with Epiducer placement may occur. But these problem-solving techniques may help in troubleshooting.

Use of the Sideguard (Cappella) stent in bifurcation lesions: a real-world experience.

AIMS: The Sideguard® stent (Cappella Medical Devices Ltd, Galway, Ireland), is a novel nitinol self-expanding dedicated bifurcation stent that flares proximally at the ostium of the side branch (SB) into a trumpet shape thereby achieving full ostial coverage. The aim of this study is to report the utility and limitations of this stent in patients undergoing treatment to bifurcation coronary lesions in a real-world setting. METHODS AND RESULTS: We prospectively identified 20 successive patients admitted over a 6-month period in whom there was significant SB disease and who were suitable for a bifurcation procedure. The Sideguard® stent was successfully used in all 20 cases including several that would have been technically difficult using conventional bifurcation techniques. We highlight use of this system using five illustrative cases that illustrate its utility and limitations in the treatment of bifurcation lesions. CONCLUSIONS: The Sideguard® stent can be used to treat complex bifurcation lesions in a straight forward manner and is not subject to the limitations associated with conventional bifurcation PCI techniques including jailing of the SB ostium and inability to fully cover/scaffold the ostium of the SB.

Os stents farmacológicos são seguros e eficazes em longo prazo? / Are drug-eluting stents safe and effective in the long term? / ¿Los stents farmacológicos son seguros y eficaces a largo plazo?

A introdução de stents farmacológicos em 2002 revolucionou a cardiologia invasiva através da redução de reestenoses. No final de 2006 surgiram relatos de aumento da incidência de trombose tardia de stent com esses stents em comparação com os de metal sem revestimento, provavelmente em decorrência do atraso de endotelização. No entanto, esses estudos continham sérias falhas metodológicas. Meta-análises posteriores mostraram de forma clara um risco apenas discretamente aumentado de trombose tardia de stent entre todos os grupos de pacientes. Um achado importante foi o de que os stents farmacológicos proporcionaram benefício significativo e mantido devido à redução de reestenose e, portanto, de revascularização de repetição. Vários registros obtidos na prática clínica confirmaram esses resultados e sugeriram que o uso de stents farmacológicos em situações mais complexas não está associado a resultados desfavoráveis. A trombose de stent é um problema multifatorial no qual o stent é apenas um dos elementos. Novos estudos serão necessários para determinar a técnica para o procedimento e o esquema antiplaquetário ideais. Os stents farmacológicos são seguros e eficazes em longo prazo, embora estudos intensivos continuem sendo realizados com o propósito de reduzir o risco de trombose de stent na próxima geração.

The introduction of drug-eluting stents in 2002 revolutionized interventional cardiology by minimizing restenosis. Reports of increased late stent thrombosis with these stents compared with bare metal stents, probably due to delayed endothelialization, emerged late in 2006. These studies contained serious methodological flaws, however. Subsequent meta-analyses clearly showed only a small incremental risk of late stent thrombosis across all patient groups. Importantly, a significant and sustained benefit of drug-eluting stents due to reduced restenosis and thus repeat revascularization was also shown. Several 'real-world' registries have confirmed these results and suggested that the use of these stents in more complex situations is not associated with adverse outcomes. Stent thrombosis is a multifactorial problem, in which the stent is only one element. Further research is required to determine optimal procedural technique and antiplatelet regimens. Drug-eluting stents are safe and effective in the long-term, though intensive research continues into ways to reduce the risk of stent thrombosis in the next generation.

La introducción de stents farmacológicos en 2002 revolucionó la cardiología invasiva a través de la reducción de reestenosis. En el final de 2006 surgieron relatos de aumento de la incidencia de trombosis tardía de stent con esos stents en comparación con los de metal sin revestimientos, probablemente en consecuencia del atraso de endotelización. Mientras tanto, esos estudios contenían serias fallas metodológicas. Metanálisis posteriores mostraron de forma clara un riesgo apenas discretamente aumentado de trombosis tardía de stent entre todos los grupos de pacientes. Un hallazgo importante fue el de que los stents farmacológicos proporcionaron beneficio significativo y mantenido debido a la reducción de reestenosis y, por lo tanto, de revascularización de repetición. Varios registros obtenidos en la práctica clínica confirmaron esos resultados y sugirieron que el uso de stents farmacológicos en situaciones más complejas no está asociado a resultados desfavorables. La trombosis de stent es un problema multifactorial en el cual el stent es apenas uno de los elementos. Nuevos estudios serán necesarios para determinar la técnica para el procedimiento y el esquema antiplaquetario ideales. Los stents farmacológicos son seguros y eficaces a largo plazo, aunque estudios intensivos continúen siendo realizados con el propósito de reducir el riesgo de trombosis de stent en la próxima generación.

Are drug-eluting stents safe and effective in the long term?

The introduction of drug-eluting stents in 2002 revolutionized interventional cardiology by minimizing restenosis. Reports of increased late stent thrombosis with these stents compared with bare metal stents, probably due to delayed endothelialization, emerged late in 2006. These studies contained serious methodological flaws, however. Subsequent meta-analyses clearly showed only a small incremental risk of late stent thrombosis across all patient groups. Importantly, a significant and sustained benefit of drug-eluting stents due to reduced restenosis and thus repeat revascularization was also shown. Several 'real-world' registries have confirmed these results and suggested that the use of these stents in more complex situations is not associated with adverse outcomes. Stent thrombosis is a multifactorial problem, in which the stent is only one element. Further research is required to determine optimal procedural technique and antiplatelet regimens. Drug-eluting stents are safe and effective in the long-term, though intensive research continues into ways to reduce the risk of stent thrombosis in the next generation.

Circumstances and mode of in-hospital death following 9,914 consecutive patients undergoing percutaneous coronary interventions in the northwest of England.

AIM: To better describe the epidemiological causes of in-hospital death after percutaneous coronary intervention (PCI) in the present stent era. METHODS: Systematic review of all in-hospital deaths following PCI in North West England from 2001 to 2003. Sixty-two in-hospital deaths (0.6%) were identified from 9,914 consecutive PCIs performed during the study period. The medical records of 4 patients were missing, leaving 58 patients to be reviewed with a standard data extraction tool to determine a circumstance and a mode of death. Medical records were reviewed at each center and cases were discussed at regional consensus meetings. All the collected data were validated by random cross-checking of data by exchange site visits. Multivariate logistic regression was used to identify risk factors for deaths related to procedural complications. RESULTS: Low output failure was the most common mode of death, occurring in 42 patients (72.4%). The circumstance of death was a procedural complication in 35 patients (60.3%), and preexisting acute cardiac disease in 23 patients (39.7%). Significant predictors of death from procedural complications were treatment of left main stem (odds ratio [OR] 13.8; p < 0.001) or graft lesions (OR 5.6; p < 0.001), and female sex (OR 3.0; p = 0.002). CONCLUSIONS: Procedural complications account for over half of all post-PCI deaths. We have identified several risk factors that may help reduce the number of deaths related to procedural complications.

Young Adult Myocardial Infarction and Ischemic Stroke: the role of paradoxical embolism and thrombophilia (The YAMIS Study).

OBJECTIVES: We aimed to investigate the frequency of venous-to-arterial circulation shunts (v-aCS), usually caused by patent foramen ovale (PFO), and thrombophilia in young adults suffering myocardial infarction (MI) and ischemic stroke (IS) and matched healthy control subjects. BACKGROUND: The cause of MI and IS in young adults is often uncertain, and paradoxical embolism might be more frequent than previously thought. METHODS: Young adults (ages 16 to 39 years) surviving MI (n = 101) and IS (n = 101) between 1993 and 1998 were matched by age and gender to 202 control subjects from the same general practitioner practices. The v-aCS were detected by transcranial Doppler after intravenous microbubble ultrasound contrast; "significant" v-aCS (> or =15 microbubble emboli) correlated with PFO on transesophageal echocardiography. A "major" v-aCS was >50 microbubbles spontaneously or >10 microbubbles spontaneously with >80 after provocation. Venous blood was taken for a thrombophilia screen. RESULTS: Myocardial infarction, more frequent in men, was associated with the usual cardiovascular risk factors. More women suffered IS, which was associated only with migraine and hypertension. Neither "significant" nor "major" v-aCS were associated with MI. "Major" v-aCS was found in 24 (25%) IS cases compared with 12 (12%) control subjects (odds ratio 2.80, 95% confidence interval 1.21 to 6.84; p = 0.016). Thrombophilia was not significantly associated with either MI or IS. CONCLUSIONS: Only "major" v-aCS were associated with stroke in young adults. Closure of smaller v-aCS might not be justified.

Doctors, patients and the Internet: time to grasp the nettle.

The Internet, the fastest growing technology in society, has been driven by the public's hunger for fast, cheap communication. The modern patient increasingly presents to their doctor with an Internet diagnosis and treatment plan, obtained from a website with inaccurate or highly biased information. Doctors have limited access to the Internet in the workplace and often find it difficult to answer specific medical questions using routine search engines. The Internet provides an unparalleled opportunity to revolutionise medical education, bedside decision-making, patient records and communication between professionals and patients. Coordination between government, the Royal Colleges and the healthcare industry is required to develop the necessary software and hardware to help doctors and patients use the Internet to their advantage.